Related Experiment Videos

Pulmonary Biomarkers of Bronchopulmonary Dysplasia

Alecia Thompson1, Vineet Bhandari

  • 1Department of Pediatrics, Division of Perinatal Medicine, Yale University School of Medicine, New Haven, CT 06520.

Biomarker Insights
|May 12, 2009
PubMed

Insights

Bronchopulmonary dysplasia (BPD) in premature infants is linked to altered immune mediators called cytokines. Understanding these biomarkers is key to managing this chronic lung disorder.

Area of Science:

  • Neonatal Medicine
  • Pulmonology
  • Biochemistry

Background:

  • Bronchopulmonary dysplasia (BPD) is a significant cause of illness and death in premature infants, often requiring oxygen at 36 weeks postmenstrual age.
  • The development of BPD is multifactorial, involving prematurity, mechanical ventilation, and oxygen exposure.
  • Cytokines, immune mediators, play a crucial role in BPD pathogenesis, with imbalances in pro-inflammatory and anti-inflammatory cytokines associated with disease onset and severity.

Purpose of the Study:

  • To review the physiological roles of specific pulmonary biomarkers in premature neonates.
  • To examine how perturbations in these biomarkers contribute to the development of BPD.
  • To discuss the proposed associations between these biomarkers and BPD.

Main Methods:

  • Review of existing literature on BPD pathogenesis and biomarkers.
  • Analysis of studies investigating cytokine alterations in premature infants.
  • Examination of pulmonary markers related to lung repair, endothelial integrity, oxidative damage, and fibrinolysis.

Main Results:

  • Alterations in pro-inflammatory and anti-inflammatory cytokine levels are observed in BPD.
  • Other pulmonary markers, including those for lung repair, endothelial integrity, oxidative stress, and fibrinolysis, are also modified in BPD.
  • These biomarker derangements are implicated as contributing mechanisms in BPD development.

Conclusions:

  • Cytokines and other pulmonary biomarkers are critically involved in the pathogenesis of bronchopulmonary dysplasia.
  • Further research into these biomarkers may offer insights into predicting and managing BPD in premature infants.
  • Understanding biomarker derangements is essential for addressing the mechanisms underlying BPD.

Related Concept Videos

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features01:24

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies01:27

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Pulmonary Function Tests01:25

Pulmonary Function Tests

Pulmonary Function Tests (PFTs)
Pulmonary Function Tests are crucial diagnostic tools for assessing respiratory function, particularly in patients with chronic respiratory disorders. They comprehensively evaluate lung volumes, ventilatory function, breathing mechanics, diffusion, and gas exchange. These tests help diagnose pulmonary diseases and play a significant role in monitoring disease progression, evaluating disability, and assessing response to therapy.
PFTs involve using a spirometer, a...
Chronic Obstructive Pulmonary Disease II: Emphysema01:23

Chronic Obstructive Pulmonary Disease II: Emphysema

Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.
Chronic Obstructive Pulmonary Disease-I: Introduction01:20

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations01:19

Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations

Chronic Obstructive Pulmonary Disease, or COPD, is a long-term condition marked by persistent and only partially reversible airflow limitation. It involves two overlapping conditions—chronic bronchitis and emphysema—which often co-appear but differ in dominant symptoms and underlying mechanisms.Chronic Bronchitis FeaturesChronic bronchitis presents with a persistent productive cough and thick, sometimes purulent mucus due to airway inflammation, enlarged mucus glands, and goblet cell...